Skip to content

Compounds · Metabolic & weight · Treatment of obesity and metabolic disorders

Cagrilintide

Full protocol

NNC0174-0833, AM833, NN9838

Long-acting amylin analog in Phase 3 development for weight management, mimicking amylin’s satiety and gastric-slowing effects. Being developed alone and combined with semaglutide (CagriSema) for greater weight loss than either drug alone.

0.25 → 2.4 mg weekly, titrated

Research score 85/100. Reference only, not a prescription.

  • Appetite Suppression
  • Metabolic Enhancement
  • Blood Sugar Control
  • GLP-1 Agonist
  • Gut Health
US status
Investigational
Approval
Phase 2/3 Clinical Trial
Evidence
Phase 3 trials (REDEFINE). Often studied with semaglutide (CagriSema).
Research score
85 / 100
Indication
Obesity/Weight Management
Origin
Denmark
Source category
Digestive System
Status group
Investigational

Mechanism

Agonizes calcitonin receptors, activating cAMP/PKA signaling in hypothalamic neurons to boost satiety, while slowing gastric emptying and suppressing after-meal glucagon; structural modifications extend its half-life for infrequent dosing.

Safety file

Nausea and vomiting are common; no increased pancreatitis signal so far, and cardiovascular profile appears favorable.

  • Nausea
  • Decreased appetite
  • Injection site reactions
  • Gastrointestinal disturbances

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water
5 mg5 mg/mL2.5 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard titration (once weekly, subcutaneous)

  • Mirrors semaglutide: weeks 1 to 4 0.25 mg, weeks 5 to 8 0.5 mg, weeks 9 to 12 1.0 mg, weeks 13 to 16 1.7 mg, then 2.4 mg as maintenance
  • Hold each step 4 weeks

Commonly stacked

  • Cagrilintide is an amylin analogue and is often paired with semaglutide, since the two work by different mechanisms and the combination outperforms either alone
  • When stacking, titrate each on its own schedule, same day, different injection sites

Dosing detail

  • Start at 0.25 mg weekly and step up every 4 weeks to 2.4 mg, the same shape as semaglutide.
  • Trials have gone as high as 4.5 mg weekly, but 2.4 mg is the common maintenance target.
  • Often run alongside semaglutide for greater effect than either alone.
  • One day per week. Long-acting, so timing is forgiving.

Duration

  • Titrate over ~16 weeks, then maintain. Some reduce to 1.8 to 2.0 mg weekly once at goal to hold results.

Notes

  • An amylin analogue, so it works on satiety differently than the GLP-1 drugs and stacks well with them.
  • Inject subcutaneously and rotate sites.
  • Nausea is the usual early effect.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard